Efficacy of plant-produced recombinant antibodies against HCG

Kathuria, S.; Sriraman, Rajan; Nath, R.; Sack, Markus; Pal, Rahul; Artsaenko, Olga; Talwar, G.P.; Fischer, Rainer; Finnern, Ricarda

doi:10.1093/humrep/17.8.2054

Cited by 79 publications

(58 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The antibody, cPiPP, is a chimeric recombinant anti-hCGβ antibody engineered from a mouse monoclonal antibody raised against hCGβ [22]. The heavy chain variable region gene of a mouse monoclonal antibody [26] was fused to the human IgG 1 constant region, while the light chain variable region gene was fused to the human kappa constant region.…”

Section: Methodsmentioning

confidence: 99%

See 1 more Smart Citation

Selective Killing of Leukemia and Lymphoma Cells Ectopically Expressing hCGβ by a Conjugate of Curcumin with an Antibody against hCGβ Subunit

Vyas

Pal²,

Vishwakarma

et al. 2009

Oncology

View full text Add to dashboard Cite

Objective: A variety of cancers ectopically express human chorionic gonadotropin beta (hCGβ). Patients harboring such cancers have poor prognosis and adverse survival. A recombinant chimeric antibody, cPiPP, exhibiting high affinity and specificity for hCGβ/hCG was engineered. This study was designed to determine whether this antibody alone or conjugated to curcumin can selectively kill tumor cells expressing hCGβ. Experimental Design: The study was carried out on MOLT-4 and U-937 cells expressing hCGβ and on peripheral blood leukocytes of acute myeloid leukemia (AML) patients. The anticancerous compound curcumin was conjugated to cPiPP. The binding of cPiPP and cPiPP-curcumin conjugate to cells was studied by flow cytometry and cytotoxicity by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT), FACS with propidium iodide staining, trypan blue exclusion assay and microscopy. Results: The antibody did not impair the growth of MOLT-4 and U-937 cells in culture. Its conjugate with curcumin, however, was lethal to both cell lines. The immunoconjugate killed tumor cells bearing the CD33 marker of an AML patient expressing hCGβ but did not have a similar action on cells of another AML patient with the CD13 marker but who was negative for hCGβ. Conclusion: A humanized antibody against hCGβ linked to curcumin has potential for therapy of hCGβ-expressing tumors.

show abstract

Section: Methodsmentioning

confidence: 99%

“…Both synthesize and expose hCG on their membranes. A recombinant chimeric anti-hCG antibody, cPiPP, developed earlier [22], binds with over 95% of MOLT-4 cells as determined by flow cytometery [23]. On the other hand, this antibody exhibited no binding to peripheral blood mononuclear cells (PBMC) of normal healthy donors [23].…”

Section: Introductionmentioning

confidence: 99%

Selective Killing of Leukemia and Lymphoma Cells Ectopically Expressing hCGβ by a Conjugate of Curcumin with an Antibody against hCGβ Subunit

Vyas

Pal²,

Vishwakarma

et al. 2009

Oncology

View full text Add to dashboard Cite

show abstract

“…82 In both cases, plants were used to produce the fullsize IgG as well as scFv and diabody derivatives. The second approach involves the use of plant viruses as vectors.…”

Section: Major Milestonesmentioning

confidence: 99%

Antibodies from plants for bionanomaterials

Edgue

Twyman²,

Beiss

et al. 2017

WIREs Nanomed Nanobiotechnol

View full text Add to dashboard Cite

Antibodies are produced as part of the vertebrate adaptive immune response and are not naturally made by plants. However, antibody DNA sequences can be introduced into plants, and together with laboratory technologies that allow the design of antibodies recognizing any conceivable molecular structure, plants can be used as 'green factories' to produce any antibody at all. The advent of plant-based transient expression systems in particular allows the rapid, convenient, and safe production of antibodies, ranging from laboratory-scale expression to industrial-scale manufacturing. The key features of plant-based production include safety, speed, low cost, and convenience, allowing newcomers to rapidly master the technology and use it to its full advantage. Manufacturing in plants has recently achieved significant milestones and offers more than just an alternative to established microbial and mammalian cell platforms. The use of plants for product development in particular offers the power and flexibility to easily coexpress many different genes, allowing the plug-and-play construction of novel bionanomaterials, perfectly complementing existing approaches based on plant virus-like particles. As well as producing single antibodies for applications in medicine, agriculture, and industry, plants can be used to produce antibody-based supramolecular structures and scaffolds as a new generation of green bionanomaterials that promise a bright future based on clean and renewable nanotechnology applications. © 2017 The Authors. WIREs Nanomedicine and Nanobiotechnology published by Wiley Periodicals, Inc. How to cite this article:WIREs Nanomed Nanobiotechnol 2017, 9:e1462. doi: 10.1002/wnan.1462 INTRODUCTIONA ntibodies are glycoproteins produced by the adaptive immune system in humans and other vertebrates. They recognize and bind particular target antigens with great affinity and specificity, allowing them to clear pathogens and other unwanted material from the body. Although plants do not naturally produce antibodies, they can be engineered to do so by introducing the corresponding immunoglobulin genes. 1,2 In this manner, plants can be instructed to make antibodies that target any antigen of choice, and they can make them efficiently and in all kinds of different formats. 3,4 Most people picture antibodies as the typical mammalian serum-type immunoglobulin G (IgG), which comprises two identical heavy chains and two identical light chains joined by disulfide bonds (Figure 1). The chains fold and assemble into a multimeric Y-shaped structure. Below the hinge, in what is known as the Fc region (fragment crystallizable), all IgG molecules are largely the same, and this region is responsible for the general effector functions of antibodies, such as immune cell recognition and complement fixation. This part of the antibody is also glycosylated. The hinge and the region above, where the antibody branches into its characteristic Y-shape, is known as the F(ab 0 ) 2 or Fab (fragment for antigen This is an open access article under ...

show abstract

“…PiPP was converted into a recombinant chimeric antibody (cPiPP) as described elsewhere. 40 Recombinant antibodies for clinical therapeutic use in humans are expressed in low yields in mammalian cells, which accounts for their high cost. To cut costs, cPIPP was expressed as a periplasmic protein in tobacco leaves at a high yield of 20 mg of purified protein per Kg fresh tobacco leaves.…”

Section: Recombinant Humanized and Chimeric Antibodiesmentioning

confidence: 99%

Immunological Approaches Against Human Chorionic Gonadotropin for Control of Fertility and Therapy of Advanced‐Stage Cancers Expressing hCG/Subunits

Talwar¹,

Gupta²,

Shankar³

2011

American J Rep Immunol

View full text Add to dashboard Cite

Citation Talwar GP, Gupta JC, Shankar NV. Immunological approaches against human chorionic gonadotropin for control of fertility and therapy of advanced‐stage cancers expressing hCG/subunits. Am J Reprod Immunol 2011; 66: 26–39 The year 2011 marks the 84th year of the discovery of human chorionic gonadotropin (hCG) by Ascheim and Zondek. Originally considered and employed as a reliable diagnostic index for pregnancy, the multiple roles of hCG as an initiator and sustainer of pregnancy are now recognized. Besides pregnancy, the expression of hCG or its subunits is observed in a number of cancers of diverse type, in particular at advanced stage. Cancers expressing hCG/subunits have poor prognosis and adverse survival. Thus, immunological approaches against hCG have applications for control of fertility and for treatment of terminal cancers. Various mechanisms by which hCG exercises its action are discussed. These include its role as autocrine growth promoter, inhibitor of apoptosis, promotor of angiogenesis, invasiveness, and protection against rejection by the immune system. The article reviews various vaccines developed for control of fertility and for therapy of advanced‐stage cancers expressing ectopically hCG/subunits. Also reviewed are the recombinant fully humanized and chimeric antibodies usable for emergency contraception, as vacation contraceptive, and as therapeutic antibodies for treatment of cancers.

show abstract

Efficacy of plant-produced recombinant antibodies against HCG

Abstract: Passive immunization with recombinant HCG-specific antibodies may have clinical utility as (i) diagnostic and therapeutic tools for HCG-expressing cancers and (ii) contraceptive measures.

Cited by 79 publications

References 35 publications

Selective Killing of Leukemia and Lymphoma Cells Ectopically Expressing hCGβ by a Conjugate of Curcumin with an Antibody against hCGβ Subunit

Selective Killing of Leukemia and Lymphoma Cells Ectopically Expressing hCGβ by a Conjugate of Curcumin with an Antibody against hCGβ Subunit

Antibodies from plants for bionanomaterials

Immunological Approaches Against Human Chorionic Gonadotropin for Control of Fertility and Therapy of Advanced‐Stage Cancers Expressing hCG/Subunits

Contact Info

Product

Resources

About